High Cost Drugs

Executive Summary

For a number of secondary care interventions involving high-cost drugs, providers (hospitals) are not paid for provision though the normal process of the National Tariff because these drugs are disproportionately expensive compared to associated procedures and costs.

As such, the costs of these products are reimbursed directly by commissioners. Drugs on this tariff-excluded list are predominantly reimbursed by NHS England through specialised services or the Cancer Drugs Fund (CDF), however some are commissioned by Clinical Commissioning Groups (CCGs).